The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

Amidst an ongoing outbreak of a deadly bird flu virus in livestock, the US Department of Agriculture is doing more to prevent ...

MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Onradivir significantly shortens recovery time in adults with uncomplicated influenza A. Read more. Learn more.

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...

Abu Dhabi Public Health Centre (ADPHC) has vaccinated nearly 300,000 people across Abu Dhabi, Al Ain Region, and Al Dhafra with the seasonal flu vaccine as part of its 2024–2025 campaign, a 45 percent ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...